ARTICLE | Clinical News
ING-1: Began Phase I trial
November 6, 2000 8:00 AM UTC
Xoma Ltd. (XOMA), Berkeley, Calif. Product: ING-1 Business: Cancer Therapeutic category: Antibody, Cytotoxic Target: Ep-CAM intercellular adhesion molecule Description: Humanized monoclonal antibody a...